Transplantation of Endothelial Progenitor Cells: Summary and prospect

Yan, Fanchen; Li, Jing; Zhang, Wei

doi:10.1016/j.acthis.2022.151990

Cited by 11 publications

(12 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human EPCs have also been confirmed to be capable of forming a neovasculature in a critical-sized rat bone defect model, indicating that EPCs may be directly involved in the process of angiogenesis via differentiation into lumen-forming cells [45]. Furthermore, the expressions of proangiogenic vascular endothelial growth factors are higher in EPCs or EPCs/MSCs groups compared with those in MSCs alone, as well as the formation of blood vessels, confirming that EPCs are capable of initiating a host angiogenic response through cytokine secretion [44][45][46]. Considering that EC sources are limited in the craniofacial bone defect area, the EPCs, which are potentially derived from umbilical cord blood, peripheral blood, bone marrow, or human-induced pluripotent stem cells, are of great importance in vascular engineering because of their pluripotency and outstanding self-proliferation ability [41,42].…”

Section: Cell Sources For Craniofacial Bone Vascularizationmentioning

confidence: 80%

“…Considering that EC sources are limited in the craniofacial bone defect area, the EPCs, which are potentially derived from umbilical cord blood, peripheral blood, bone marrow, or human-induced pluripotent stem cells, are of great importance in vascular engineering because of their pluripotency and outstanding self-proliferation ability [41,42]. Studies have demonstrated that postnatal neovascularization is both directly and indirectly stimulated by EPCs [43,44]. Human EPCs have also been confirmed to be capable of forming a neovasculature in a critical-sized rat bone defect model, indicating that EPCs may be directly involved in the process of angiogenesis via differentiation into lumen-forming cells [45].…”

Section: Cell Sources For Craniofacial Bone Vascularizationmentioning

confidence: 99%

See 1 more Smart Citation

Vascularization Reconstruction Strategies in Craniofacial Bone Regeneration

Chen,

Da,

Yang

et al. 2024

Coatings

View full text Add to dashboard Cite

Craniofacial bone defects are usually secondary to accident trauma, resection of tumor, sever inflammation, and congenital disease. The defects of craniofacial bones impact esthetic appearance and functionality such as mastication, pronunciation, and facial features. During the craniofacial bone regeneration process, different osteogenic cells are introduced, including primary osteoblasts or pluripotent stem cells. However, the defect area is initially avascular, resulting in the death of the introduced cells and failed regeneration. Thus, it is vital to establish vascularization strategies to build a timely and abundant blood vessel supply network. This review paper therefore focuses on the reconstruction of both osteogenesis and vasculogenesis. The current challenges, various strategies, and latest efforts applied to enhance vascularization in craniofacial bone regeneration are discussed. These involve the application of angiogenic growth factors and cell-based vascularization strategies. In addition, surface morphology, porous characters, and the angiogenic release property of scaffolds also have a fundamental effect on vasculogenesis via cell behavior and are further discussed.

show abstract

Section: Cell Sources For Craniofacial Bone Vascularizationmentioning

confidence: 80%

Section: Cell Sources For Craniofacial Bone Vascularizationmentioning

confidence: 99%

Vascularization Reconstruction Strategies in Craniofacial Bone Regeneration

Chen,

Da,

Yang

et al. 2024

Coatings

View full text Add to dashboard Cite

show abstract

“…On the one hand, EPCs differentiate into new VECs by themselves and participate in angiogenesis, and this type of angiogenesis does not rely on the existing vascular system 59 . On the other hand, these cells rely on their own paracrine effect and secrete some growth factors and other proangiogenic substances to indirectly participate in angiogenesis 60 .…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel disease

Cai,

Li,

Gao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Ischaemic bowel disease (ICBD) is a group of intestinal ischaemia syndromes caused by various aetiologies of reduced intestinal blood flow or vascular occlusion. ICBD can present as abdominal pain, bloody stool, and diarrhoea. This disease often occurs in middle-aged and elderly individuals with cardiovascular and cerebrovascular diseases. The incidence of ischaemic bowel disease has been increasing for decades, and it is difficult to diagnose, resulting in rapid disease progression and a high mortality rate. Therefore, fully understanding this disease, improving the diagnosis rate of this disease, and finding appropriate treatment methods are urgently needed to improve the condition and prognosis of patients. Umbilical cord blood stem cells are accessible, have weak immunogenicity, and have various biological functions, such as angiogenesis, inflammation and immune regulation. Many studies have confirmed that cord blood stem cells can relieve ischaemia, and these cells have attracted tremendous amounts of attention in regenerative medicine in recent years. In this paper, we discuss the clinical characteristics of ICBD, analyse the characteristics of human umbilical cord blood mononuclear cells (HUCB-MNCs), and use its to treat ischaemic bowel disease. Additionally, we compare the clinical manifestations and related indicators before and after treatment to evaluate the efficacy and safety of these methods.

show abstract

“…These cells, when signaled by chemokines, migrate from the bone marrow to injury sites, promoting repair. They not only differentiate to form new vascular networks but also release vital angiogenic growth factors and exosomes, fostering endogenous neurogenesis and functional recovery [ 97 – 99 ].…”

Section: Vascular-related Exosomes and Neurotrauma Therapymentioning

confidence: 99%

Non-stem cell-derived exosomes: a novel therapeutics for neurotrauma

Nie,

Yuan,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Neurotrauma, encompassing traumatic brain injuries (TBI) and spinal cord injuries (SCI) impacts a significant portion of the global population. While spontaneous recovery post-TBI or SCI is possible, recent advancements in cell-based therapies aim to bolster these natural reparative mechanisms. Emerging research indicates that the beneficial outcomes of such therapies might be largely mediated by exosomes secreted from the administered cells. While stem cells have garnered much attention, exosomes derived from non-stem cells, including neurons, Schwann cells, microglia, and vascular endothelial cells, have shown notable therapeutic potential. These exosomes contribute to angiogenesis, neurogenesis, and axon remodeling, and display anti-inflammatory properties, marking them as promising agents for neurorestorative treatments. This review provides an in-depth exploration of the current methodologies, challenges, and future directions regarding the therapeutic role of non-stem cell-derived exosomes in neurotrauma.

show abstract

Transplantation of Endothelial Progenitor Cells: Summary and prospect

Cited by 11 publications

References 126 publications

Vascularization Reconstruction Strategies in Craniofacial Bone Regeneration

Vascularization Reconstruction Strategies in Craniofacial Bone Regeneration

Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel disease

Non-stem cell-derived exosomes: a novel therapeutics for neurotrauma

Contact Info

Product

Resources

About